Company Description

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States.

The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors.

It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.

Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Qualigen Therapeutics, Inc.

Country	United States
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Kevin Richardson

Contact Details

Address: 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 United States
Phone	760 452 8111
Website	qlgntx.com

Stock Details

Ticker Symbol	QLGN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001460702
CUSIP Number	74754R103
ISIN Number	US74754R2022
Employer ID	26-3474527
SIC Code	2834

Key Executives

Name	Position
Kevin A. Richardson II	Interim Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board
Michael S. Poirier	Chief Operating Officer
Robert W. Campbell Becher	President and Independent Director
Christopher L. Lotz	Vice President of Finance and Corporate Secretary

Latest SEC Filings

Date	Type	Title
Dec 19, 2024	EFFECT	Notice of Effectiveness
Dec 9, 2024	S-1	General form for registration of securities under the Securities Act of 1933
Nov 22, 2024	D	Notice of Exempt Offering of Securities
Nov 21, 2024	8-K/A	[Amend] Current report
Nov 21, 2024	8-K	Current Report
Nov 14, 2024	10-Q	Quarterly Report
Nov 13, 2024	8-K	Current Report
Nov 8, 2024	8-K	Current Report
Nov 1, 2024	8-K	Current Report
Oct 29, 2024	8-K	Current Report

View All SEC Filings